PALO ALTO, CA, USA I November 1, 2013 I Cellular Biomedicine Group, Inc. (CBMG) is pleased to announce that it has treated the final patient of its Phase I/IIa clinical trial for ReJoin™, a human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial tests the safety and efficacy of intra-articular injections of autologous (patient’s own) haMPCs in order to reduce inflammation and repair damaged joint cartilage.
The clinical trial is conducted by Shanghai’s Renji Hospital, a tertiary hospital affiliated with Shanghai Jiao Tong University School of Medicine. As previously reported, the interim analysis of the trial demonstrated that patients had a clinically meaningful reduction in pain and increase in mobility, with a significant improvement (P
Full data analysis by FuDan Medical University Department of Biostatistics will be carried out in the next four to six weeks and the final report of the trial will be announced before the end of the year.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
SOURCE: Cellular Biomedicine Group
Post Views: 141
PALO ALTO, CA, USA I November 1, 2013 I Cellular Biomedicine Group, Inc. (CBMG) is pleased to announce that it has treated the final patient of its Phase I/IIa clinical trial for ReJoin™, a human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial tests the safety and efficacy of intra-articular injections of autologous (patient’s own) haMPCs in order to reduce inflammation and repair damaged joint cartilage.
The clinical trial is conducted by Shanghai’s Renji Hospital, a tertiary hospital affiliated with Shanghai Jiao Tong University School of Medicine. As previously reported, the interim analysis of the trial demonstrated that patients had a clinically meaningful reduction in pain and increase in mobility, with a significant improvement (P
Full data analysis by FuDan Medical University Department of Biostatistics will be carried out in the next four to six weeks and the final report of the trial will be announced before the end of the year.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
SOURCE: Cellular Biomedicine Group
Post Views: 141
